

Government of India  
Directorate General of Health Services  
Central Drugs Standard Control Organization  
(FDC Division)

FDA Bhawan, Kotla Road  
New Delhi-110002

Dated:

To,

M/s. Alkem Health Science,  
A Unit of Alkem Laboratories Ltd., Unit-2,  
Samardung, Karek Block, Namthang,  
Sikkim Namthang-737137.

19 AUG 2021

**Subject:** Permission to conduct Phase III clinical trial with the FDC of Sitagliptin Phosphate IP eq. to Sitagliptin 100mg + Dapagliflozin 10mg tablets (Vide protocol no. ALK25-DAS1 version no. 2.0, dated: 28.07.2021)-regarding.

Dear Sir,

With reference to your online application submitted in Form CT-21 on dated 17.03.2021 please find enclosed herewith the "permission to conduct clinical trial study of new drug" bearing no. CT-06-129/2021 under the provision of Drugs and Cosmetics Act and Rules. The permission is subject to the conditions mentioned below.

Kindly acknowledge receipt to this letter and its enclosures.

Yours faithfully,

(Dr. V. G. Somani)  
Drugs Controller General (India)

**CONDITIONS OF PERMISSION**

- I. Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;
- II. Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
  - i. Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be;
  - ii. Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- III. In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- IV. The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

Permission no.: CT-06-129/2021

1. The Central Licencing Authority hereby permits **M/s. Alkem Health Science, A Unit of Alkem Laboratories Ltd., Unit-2, Samardung, Karek Block, Namthang, Sikkim Namthang-737137.** (Name and full address with contact details of the applicant) to conduct clinical trial of the new drug or investigational new drug as per protocol number **ALK25-DAS1 version no. 2.0, dated: 28.07.2021** in the below mentioned clinical trial sites.
2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi

Date: .....

**19 AUG 2021**

  
Central Licencing Authority  
Stamp

Dr. V. G. SOMANI  
Drugs Controller General (India)  
Dte. General of Health Services  
Ministry of Health and Family Welfare  
FDA Bhawan, Kotla Road, I.T.O.  
New Delhi-110002

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug:	Sitagliptin Phosphate IP eq. to Sitagliptin 100mg + Dapagliflozin 10mg tablets
Therapeutic class:	Antidiabetic
Dosage form:	Tablets
Composition:	Sitagliptin Phosphate IP eq. to Sitagliptin 100mg + Dapagliflozin 10mg tablets
Indications:	In patients with Type 2 diabetes mellitus (T2DM) who are on background therapy of Metformin

Details of clinical trial site:

Names and address of clinical trial site:	As per annexure- A
Ethics committee details:	As per annexure- A
Name of principal investigator:	As per annexure- A

Permission no.: CT-06-129/2021

S. No.	Name of PI	Site Name	Ethics Committee Name, Address & EC registration No
1	Dr. Dhiraj Kishore	Department of Medicine, IMS BHU, Varanasi-221005, Uttar Pradesh	Institutional Ethics Committee, IMS BHU, Varanasi-221005, Uttar Pradesh ECR/526/Inst/UP/2014/RR-20
2	Dr. Sher Singh Dariya	SMS Medical College and Attached Hospitals, JLN Marg, Jaipur-302004, Rajasthan	Ethics Committee SMS Medical College and Attached Hospitals, JLN Marg, Jaipur-302004, Rajasthan ECR/26/Inst/RJ/2013/RR-19
3	Dr. Surender Kumar	Sir Ganga Ram Hospital, SGRH Marg, Rajinder Nagar, New Delhi-110060	Sir Ganga Ram Hospital Ethics Committee, Room No. 1643, 6 <sup>th</sup> Floor, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi-110060 ECR/20/Inst/DL/2013/RR-2019
4	Dr. Anirban Sinha	Medical College and Hospital, 88 College Street Kolkata-700073	Institutional Ethics Committee for Human Research Medical College and Hospital 88 College Street Kolkata-700073 ECR/287/Inst/WB/2013/RR-19
5	Dr. Amol Laxmanrao Dange	Lifepoint Multispecialty Hospital, 145/1, Mumbai Bangalore Highway, Near Hotel Sayaji, Wgkad, Pune-411057, Maharashtra.	LPR Ethics Committee, Lifepoint Multispecialty Hospital, 145/1, Mumbai Bangalore Highway, Near Hotel Sayaji, Wakad, Pune-411057, Maharashtra ECR/751/Inst/MH/2015/RR-21

Place: .....

Date: .....

19 AUG 2021



Central Licencing Authority

Stamp

Dr. V. G. SOMANI

Drugs Controller General (India)  
Dte. General of Health Services  
Ministry of Health and Family Welfare  
FDA Bhawan, Kotla Road, I.T.O.  
New Delhi-110002